CClinicalTrials.gg
Status unknownNCT05126732Updated Nov 19, 2021

Ganglion Cell Thickness in Enuresis Nocturna

An observational study in Enuresis, Nocturnal, Ganglion and Circadian Rhythm Disorders, sponsored by Izmir Bakircay University. Status unknown at 1 site in Turkey. Open to participants aged 5 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Izmir Bakircay University · Observational

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
5 Years to 18 Years
Sex
All
01

Study summary

The precise role of the intrinsic circadian regulatory mechanism behind the pathogenesis of enuresis is not fully understood, but in theory, circadian rhythm irregularity may be the primary pathogenic mechanism not only for urinary outflow mechanisms but also for nocturnal bladder function. The proximity between SCN centers that control AVP release, sleep/arousal, voiding, and baroreregulation may provide the basis for circadian rhythm disturbance in one or more of these biological functions. Ganglion cells containing melanopsin pigment in the retina transmit the information they receive from the outside world about the light-dark state to the SCN via the retinohypothalamic pathway. Peripapillary retinal nerve fiber layer (RNFL) thickness, optic nerve head and macula are examined most frequently for the diagnosis of glaucoma and the detection of progression with optical coherence tomography (OCT). If differences in ganglion cell thickness can be detected using OCT in these children, a new avenue in Enuresis Nocturna may be opened.

02

Conditions studied

  • Enuresis, Nocturnal
  • Ganglion
  • Circadian Rhythm Disorders

Keywords

  • enuresis
  • optical coherence tomography
03

In context

Ganglion Cysts

136 studies on the registry are indexed under Ganglion Cysts; 28 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 28 observational studies indexed under Ganglion Cysts.

Browse Ganglion Cysts studies →

Lead sponsor

Izmir Bakircay University is the lead sponsor of 73 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients aged 5-18 years, with enuresis, without any eye disease

Inclusion criteria

  • be between the ages of 5-18
  • have enuresis

Exclusion criteria

Exclusion Criteria:

  • have any eye conditions
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Difference in ganglion cell thickness in enuretic children

    Normal values in RNFL measurements on OCT 75 (lowest)-107.2 (highest)

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
  • Bakircay University
    Izmir, Turkey
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05126732
Lead sponsor
Izmir Bakircay University
Responsible party
Yasar Issi (Asistant Professor, Izmir Bakircay University) — Principal investigator
First posted
Nov 19, 2021
Start date
Jan 2022 (estimated)
Primary completion
Apr 2022 (estimated)
Completion
Jul 2022 (estimated)
Last update
Nov 19, 2021

Study contacts

Yasar ISSI
Contact
yasarissi@yahoo.com
00905321704131

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion